Evidence map›Paper›PMID 40745077›Full record

ArticleJournal of neuro-oncology2025

Recurrent meningioma treated with boron neutron capture therapy: a feasibility study with dosimetric and clinical correlates.

Tien-Li Lan, Chun-Fu Lin, Yi-Yen Lee, Feng-Chi Chang, Shih-Chieh Lin, Fong-In Chou, Jinn-Jer Peir, Po-Shen Pan, Jen-Kun Chen, Lu-Han Lai and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tien-Li LanSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Chun-Fu LinDepartment of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
Yi-Yen LeeSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Feng-Chi ChangDepartment of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan.
Shih-Chieh LinDepartment of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Fong-In ChouNuclear Science & Technology Development Department, National Tsing-Hua University, Hsinchu City, Taiwan.
Jinn-Jer PeirNuclear Science & Technology Development Department, National Tsing-Hua University, Hsinchu City, Taiwan.
Po-Shen PanDepartment of Chemistry, Tamkang University, New Taipei City, Taiwan.
Jen-Kun ChenInstitute of Biomedical Engineering and Nanomedicine, National Health Research Institute, Zhunan Town, Miaoli County, Taiwan.
Lu-Han LaiDepartment of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsinchu, Taiwan.
Hiroki TanakaParticle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan.
Shih-Ming HsuDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan. smhsu@nycu.edu.tw.
Yi-Wei ChenDepartment of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsinchu, Taiwan. chen6074@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBoron neutron capture therapy (BNCT) is a targeted radiotherapy modality that has shown promise in the treatment of recurrent gliomas and head and neck cancers. Although meningiomas are generally slow-growing, recent studies have demonstrated favorable uptake of boron-containing compounds, particularly boronophenylalanine (BPA), suggesting a potential role for BNCT in recurrent meningioma.

methodsWe retrospectively analyzed 13 patients with recurrent meningiomas treated with salvage BNCT at the Tsing Hua Open-Pool Reactor between August 2020 and May 2024. Tumor uptake was assessed using either ¹⁸F-BPA or ¹⁸F-Fluciclovine PET. Treatment response was evaluated using RANO criteria, and outcomes were analyzed in relation to dosimetric and clinical factors.

resultsOf the 13 patients (1 WHO grade 3, 6 grade 2, and 6 grade 1), 5 (38%) responded to BNCT. Responders had significantly higher tumor mean dose (45.10 vs. 25.85 GyE, p = 0.003). Tumor location influenced dosimetry; non-skull base tumors received higher doses and showed a trend toward better response. TNR and tumor size were not predictive of response. No severe adverse events were observed.

conclusionsSalvage BNCT is a feasible and well-tolerated treatment for recurrent meningioma, with dose distribution and tumor location significantly influencing treatment response. Further studies are warranted to refine imaging and planning strategies, particularly for skull base lesions and in the context of Fluciclovine PET.

Indexed as

Boron Neutron Capture TherapyMeningeal NeoplasmsMeningiomaNeoplasm Recurrence, LocalAdultAgedFeasibility StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesAtypical meningiomaBenign meningiomaBoron neutron capture therapyFluciclovine

Identifiers

PMID40745077
PMCPMC12420710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.